Roche sponsors new Twitter-based diabetes site; Novartis: Turkish expansion depends on market;

@FiercePharma: Fake Avastin's path to U.S. passes through fake addresses--WSJ. News | Follow @FiercePharma

> Roche ($RHHBY) is backing a new Twitter-based website curating information and conversation about diabetes, with a widget connecting to its Accu-Check Diabetes Link page. News

> Slovenian drugmaker Krka has won approval to sell its shares on the Polish stock exchange. Item

> Novartis ($NVS) says its plans for Turkish manufacturing expansion aren't certain, but hinge on its performance in the market's "challenging environment." Story

> Sanofi ($SNY) has asked a Las Vegas judge to dismiss a lawsuit alleging the sleep drug Ambien caused a local man to commit suicide. Article

> Will Purdue Pharma's new sleep drug Intermezzo catch on with doctors and patients? Report

> GE ($GE) bought SeqWright, a genomic-sequencing company that works on contract for drugmakers such as Eli Lilly ($LLY) and Roche, to further expand in personalized medicine. Story

Biotech News

@FierceBiotech: DepoVax drug and vaccine combo finds cancers that duck immune attacks. Story | Follow @FierceBiotech

@JohnCFierce: Sanofi blockbuster contender Zaltrap flunks a prostate cancer PhIII; gets priority review for colorectal cancer. Release | Follow @JohnCFierce

@RyanMFierce: Good stuff from Biogen's ($BIIB) Michael Gilman about how fibrosis has turned into a prime target for biotech (he'd know). Piece | Follow @RyanMFierce

> Cleveland BioLabs shares tank after BARDA drops support. Item

> Biotech vets back $22M A round for neuroscience startup. News

> Spectrum nabs Allos buyout as bladder cancer drug fails PhIII. Story

> Sanofi colorectal cancer contender Zaltrap suffers a PhIII trial setback. Report

> Industry Voices: The Fibrosis Stampede. Article

Medical Devices News

@FierceMedDev: Another take: MD+DI Editor Says Consumer Reports Article on Dangerous Devices is Dangerous Reporting. Item | Follow @FierceMedDev

> Article questions Consumer Reports analysis of device registration process. Report

> Covidien to snap up Oridion for about $346M. Story

> Report: Poor health to fuel CRM device growth. News

> Ex-Synthes employee fights back in generic device tussle. Article

Vaccines News

> DepoVax drug and vaccine combination cuts tumor immunosuppression. News

> Lung cancer vax improves survival in late-stage disease. Article

> Preventing a heart attack is just a shot away? Report

> GAVI Alliance could be closer to HPV vax deal. Item

CRO News

> Proteome Sciences pushes to grow beyond CRO niche. Story

> Warnex catches break in dealing with financial woes. Report

> Charles River and Metabolon partner to advance oncology research for others. Story

> Can computer games aid in pediatric clinical trials? Report

> Edge picks MPI to test 3 brain injury treatments. News

Manufacturing News

> Abbott gets more incentives for its new Ensure plant. Report

> Company tied to fake Avastin shipped other adulterated drugs. Story

> With new plant, Ranbaxy back in force in North America. Article

> Oridion picked up by Covidien, still under partial FDA ban. News

> FDA cites 32 contamination complaints at biologics maker. Item

And Finally... Eli Lilly's antipsychotic drug Zyprexa showed promise at treating anorexia in a mouse study. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.